Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Alina Markova, MD, speaks to the mechanism of action of topical ruxolitinib INCB018424 phosphate 1.5% cream vs oral ruxolitinib and other topical therapies used in the treatment of non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Uday R. Popat, MD, spoke about how well post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease was performed in this trial.
Alina Markova, MD, discusses the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Uday R. Popat, MD, spoke about the decision to use post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease.
Alina Markova, MD, highlights important findings from a study assessing topical ruxolitinib INCB018424 phosphate 1.5% cream as a treatment for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Nina Shah, MD, spoke about her key takeaways from a sub-analysis of the phase 2 KarMMa trial assessing correlates of complete response among those treated with idecabtagene vicleucel in relapsed/refractory multiple myeloma.
Nina Shah, MD, spoke about analyzing correlates of complete response in patients with relapsed/refractory multiple myeloma who were treated with idecabtagene vicleucel.
JSP191 plus fludarabine and low-dose total body radiation to target CD117 was a safe strategy to induce facilitation of full donor myeloid chimerism and clear minimal residual disease in older patients with myelodysplastic syndrome and acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.
Patients with chronic graft-vs-host disease who were administered full series of the SARS-CoV-2 vaccine displayed varied immune responses, regardless of baseline characteristics.
Patients with hematologic cancer experienced a low incidence of chronic graft-versus-host disease after receiving a regimen consisting of myeloablative hematopoietic cell transplantation and total body irradiation plus prophylactic post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil.